The development of bioactive, multi-functional, and cost-effective nanocomposite filaments for additive manufacturing (AM) is pivotal for the evolution of biomedical and healthcare sectors. Herein, an industrially scalable process is reported, to produce medical grade PA12/AgNP nanocomposites, through in-situ reactive melt-mixing, occurring within the filament extruder. Bactericidal elemental nanoparticles (Ag 0 ) were formed by silver ions (Ag + ) reducing from the Silver Nitrate (Ag 2 NO 3 ) precursor, which was suitably added to the polymer melt. Polyvinyl Alcohol (PVA) was deployed in the compound melt, as a reducing macromolecular agent. The produced nanocomposite filaments were utilized to fabricate samples with Material Extrusion (MEX) AM. A total of sixteen (16) different tests were conducted on filaments and 3D-printed samples to assess their mechanical, rheological, thermal, and antibacterial characteristics, in accordance with international standards. The nanocomposites exhibited a significant mechanical reinforcement of up to 50% compared to PA12. Additionally, the Ag-based nanocomposites demonstrated remarkable antimicrobial behavior in the presence of Staphylococcus aureus ( S. aureus ) and Escherichia coli ( E. coli ) microbes.
No takes yet. Share an insight, caveat, or question.
Vidakis et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: